News | August 11, 2021
Cadila Healthcare net profit at Rs 587.2 cr in Q1FY22
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine
Wastewater surveillance is becoming increasingly critical for community health monitoring for detecting COVID-19 outbreaks and the spread of other infectious diseases
Partnership enables broad reach of cfDNA methylation blood tests for early cancer detection
Company working on COVID vaccine INO 4800
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
Centre at Sree Chitra Tirunal Institute for Medical Sciences and Technology
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
Subscribe To Our Newsletter & Stay Updated
